Table 3 Regression analysis of correlation between mRSS and quantitative or categorical evaluation of organ involvement
| Â | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
N | β (95% CI) | N | β (95% CI) | |
Lung involvement | ||||
 KL-6 | 177 | 5.14 (−3.38 to 13.7) |  |  |
 SP-D | 170 | 1.87* (0.27 to 3.47) | 169 | 1.87* (0.09 to 3.65) |
 %FVC | 176 | − 0.64*** (− 0.98 to − 0.30) | 175 | − 0.61** (− 0.98 to − 0.23) |
 %DLco | 171 | − 0.67*** (− 1.00 to − 0.33) | 170 | − 0.53** (− 0.89 to − 0.16) |
Heart involvement | ||||
 BNP | 171 | 0.82 (− 0.02 to 1.66) |  |  |
 LVEF | 166 | 0.06 (− 0.05 to 0.17) |  |  |
 E/e’ | 136 | 0.02 (− 0.04 to 0.09) |  |  |
 RVSP | 164 | 0.11 (− 0.02 to 0.25) |  |  |
Renal involvement | ||||
 eGFR | 177 | 0.44* (0.03 to 0.85) | 176 | 0.11 (− 0.25 to 0.46) |
Gastrointestinal involvement | ||||
 Los Angeles classification | 161 | 0.02 (− 0.01 to 0.04) |  |  |
Musculoskeletal involvement | ||||
 CK | 177 | 1.99 (− 0.09 to 4.07) |  |  |